Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, double-blind randomized clinical trial FinnProstata XV. ESTO2.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517854-91-00

Acronym

ESTO2

Enrollment

400

Registered

2024-10-15

Start date

2019-08-05

Completion date

Unknown

Last updated

2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic or high-risk recurrent prostate cancer managed with androgen deprivation therapy

Brief summary

Time to disease progression after starting ADT/antiandrogen therapy

Interventions

DRUGAtorvastatin Krka 40 mg kalvopäällysteiset tabletit

DRUGIdentical capsule as the active product but without any active ingredient.

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Time to disease progression after starting ADT/antiandrogen therapy	—

Countries

Denmark, Estonia, Finland, Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026